Elexacaftor, tezacaftor and ivacaftor (ETI)

Study	Country Study period Study design	Data source	Exposure definition	Non-exposure definition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias
Etherington 2024	United Kingdom 2010 - 2023 retrospective cohort	Not specified.	Women with Cystic Fibrosis (wwCF) who became pregnant and continued elexacaftor/tezacaftor/ ivacaftor (ETI) during pregnancy.	unexposed, sick Women with Cystic Fibrosis (wwCF) who became pregnant during the pre modulator era.	at least 1st trimester, during pregnancy (anytime or not specified)	24 / 26
Etherington 2024	United Kingdom 2010 - 2023 retrospective cohort	Not specified.	A retrospective review of prospectively collected data between 2010 and 2023. Data were obtained on modality of conception, baseline demographics, mode of delivery, lactation and maternal and foetal outcomes (no other details).			24 / 26

Study	Country Study period Study design	Data source	Case	Control	Exposition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias

Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;